Viropro investor presentation 01_apr11

1,040 views

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,040
On SlideShare
0
From Embeds
0
Number of Embeds
17
Actions
Shares
0
Downloads
15
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Viropro investor presentation 01_apr11

  1. 1. Investor Presentation<br />Information contained herein this document is derived from information sources already in the public domain. It is not intended to be exhaustive, and should be read in conjunction with the other published Company information sources. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on to any other person or published, in whole or in part, for any purpose.<br />The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.<br />Viropro, Inc.<br />4199 Campus Dr., Suite 550<br />Irvine, CA 92612<br />USA<br />
  2. 2. Biotech Contract Development and Manufacturing with Asia-backed Services<br />SECTION 1<br />
  3. 3. Why Are Contract Services So Important to this Industry?<br /><ul><li>Rising costs
  4. 4. Regulatory requirements
  5. 5. Growing global competition
  6. 6. Pace of technology innovation</li></ul>Increasing the pressure on product development strategies - from drug discovery through commercial manufacturing<br />Biotech companies need us more than ever to help get their products to market as efficiently and economically as possible!<br />Viropro, Inc.<br />Confidential<br />
  7. 7. Mission Statement<br />“MAKE BIOTECH DRUGS FOR CLIENTS, EFFICIENTLY AND ECONOMICALLY.”<br />
  8. 8. The Business Recipe<br />To create the correct level of cross-border mix that will enable us to build a world-class biotech contract services company, while simultaneously allowing each entities’ entrepreneurial drive to flourish (a la a “Protean” corporation).<br />Bizplan - Confidential<br />
  9. 9. SECTION 2<br />The Changing Market Dynamics<br />
  10. 10. Does The Service Address A Viable Market?<br /><ul><li>Yes, it does. We’re NOT trying to create demand where it hasn’t already been expressed.
  11. 11. The global trend for the foreseeable future is for a continuing increase in the rate and volume of R&D that is being out-sourced by mid-to-large pharmaceutical companies.</li></ul>Confidential<br />Viropro, Inc.<br />
  12. 12. Biopharmaceutical Contract R&D and Manufacturing Market Overview<br />Growth rates moderating: 12% from 15%<br />2009 market declined <br />2011 market: $4.3 billion<br />Billion of Dollars<br />Year<br />Data Source: Industry Reports<br />Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance (48 pharmaceutical and biotechnology companies/29 CMOs)<br />
  13. 13. World Outsourced Market Volumes Mammalian Cell Culture Overview<br />Contractors Capabilities<br />No. Of Kgs<br />Year<br />Data Source: Industry Reports<br />Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance (48 pharmaceutical and biotechnology companies/29 CMOs)<br />
  14. 14. Changing Pharma/Biotech Attitudes Towards Asia-backed CDMO Services<br />In 2005, 53% of respondents would consider using a contractor outside their region<br />Will <br />Not<br />10%<br />Will <br />Not<br />Will Consider working with Asian COM<br />In 2007, 80% of respondents would consider using a contractor outside their region<br />Will Consider working with Asian COM<br />80%<br />Significant change in attitudes<br />Data Source: Industry Reports<br />Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance (48 pharmaceutical and biotechnology companies/29 CMOs)<br />
  15. 15. Pharma/Biotech Advantage to using Asian CMOs<br />Users look for substantial cost savings when using an Asian CMO<br />Data Source: Industry Reports<br />Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance (48 pharmaceutical and biotechnology companies/29 CMOs)<br />
  16. 16. Pharmaceutical and Biotechnology Companies:<br />Overview of Respondents’ Outsource<br />Strategies<br />Data Source: Industry Reports<br />Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance (48 pharmaceutical and biotechnology companies/29 CMOs)<br />
  17. 17. Biopharmaceutical Contract Development & Manufacturers:<br />Future Plans:<br />Data Source: Industry Reports<br />Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance (48 pharmaceutical and biotechnology companies/29 CMOs)<br />
  18. 18. SECTION 3<br />The Business Model for a Global Footprint<br />
  19. 19. The Global Footprint<br />Cambridge, UK<br />Montreal, CA<br />Groningen, NL<br />Pune, IN<br />Irvine-San Diego<br />Penang, MY<br />
  20. 20. “String of Pearls”<br />Future<br />Future<br />Intas<br />BPD<br />Alpha<br />Montreal<br />ESQ<br />
  21. 21. Prof. Pisano’s Model: Adapted for Viropro<br />Bioprocessing<br />MammCell Mfg.<br />Prot. Analytics<br />BacCell Mfg.<br />CRO/Other<br />VIROPRO<br />
  22. 22. Viropro, Inc.<br />To be added<br />
  23. 23. New Structure<br />VPRO<br />Malaysia<br />100%<br />Poway/San Diego<br />100%<br />ALPHA<br />ESQ<br />BPD<br />Holland<br />(76%-100%)<br />M’real<br />India<br />Bac.<br />GMP<br />Mam.<br />GMP<br />Poway<br />Camb.<br />Future India<br />(51%)<br />Malaysia<br />(100%)<br />Center of Excellence for<br />Expression Platforms & Bioprocessing<br />Center of Excellence for<br />Protein Analytics<br />Center of Excellence for<br />GMP Biomanufacturing<br />
  24. 24. SECTION 4<br />Capabilities and Core Strengths(creating a “1 + 1 equals more than 3” situation!)<br />
  25. 25. Capability<br />Cell line development<br />Preclinical material - Toxicology<br />Process development<br />Cell line<br />Scale up<br />Viropro, Inc.<br />Bulk Material is delivered for fill/finish<br />Production of clinical bulk <br />Market Supply<br />Validation<br />Cell analysis and Virus studies<br />Clinical Studies Phase I - III<br />Commercial / Phase IV<br />Other specialized service providers may be involved in delivering a complete clone-to-clinic development / manufacturing package for bacterial-, yeast- and mammalian cell culture products.<br />
  26. 26. Combined Customer Base<br />Over 100 clients, including:<br />Small to Multi-National Pharma/BioPharma<br />Biotech <br />Universities <br />CROs<br />A small sampling of our combined customer base:<br />Avecia Biologics, Bayer Bioscience, Boehringer-Ingelheim, DSM Research, Ferring, Hal Allergy, Halozyme, Henogan, Genmab, Geron, Intas Biopharmaceuticals Ltd., INSERM, King’s College, Lek Pharmaceuticals, Lonza, Lonza Biologics, Lupin Ltd., Merckle Biotech, Pfizer, Pharming Technologies, RentschlerBiotechnologi, Schering Plough, Serum Institute, UCB . . . . <br />100’s of successful projects and repeat clients <br />PROPRIETARY: DO NOT DISTRIBUTE<br />
  27. 27. Senior Management<br /><ul><li>Educated at top tier schools across North America, India and Europe:
  28. 28. MIT, UCLA, McGill, Rutgers, Nebraska, IIT-Bombay, KTH-Stockholm and others
  29. 29. 60-70% with Ph.D. / Post-Doc and M.D. experience
  30. 30. Collective work experience:
  31. 31. From Fortune 100 pharma companies to publicly-listed and startup biotech companies
  32. 32. Over 200 man-years of experience spanning biotechnology to bio-business to raising capital to marketing and sales</li></ul>Bizplan - Confidential<br />
  33. 33. Key External Advisory Board Members<br /><ul><li>Prof. Gary Pisano (HBS – in process)</li></ul>Harry E. Figgie Jr. Professor of Business Administration and Chair, Technology and Management Program, HBS, Boston, MA<br /><ul><li>Prof. Danny Wang (MIT)</li></ul>Institute Professor, Department of Chemical and Biochemical Engineering, MIT, Cambridge, MA<br /><ul><li>Dr. Howard Levine</li></ul>BioProcess Technology Consultants, Inc.<br />Massachusetts<br /><ul><li>Dr. Pete Fernandes</li></ul>Biotechnology Consultant<br />California<br />
  34. 34. SECTION 5<br />Finance Overview and Exit Valuation<br />
  35. 35. Financial Forecast Overview<br />
  36. 36. Funding Needed & Exit Strategy <br />Viropro requires a grand total of USD 40 million in two major tranches of USD 24 million (in 2011) and USD 16 million (in 2012), respectively, for key acquisitions; for getting GMP accreditation; and working capital for 2 years until we reach a net positive cash flow position<br />Funding required can be in form of equity/debt, preference share with fixed yield, soft loan or a combination of the above. Exit will depend on the investors’ strategy<br />The method or vehicle used by the investor to exit will depend on their preference. Exit could be by any of the following methods:<br /><ul><li>Exit to the Market
  37. 37. Listing on Singapore / Indian Stock Exchanges
  38. 38. Strategic Trade Sale
  39. 39. Global Integration, Merger or Acquisition </li></li></ul><li>Project Cost & Funding - 1<br />Bizplan - Confidential<br />
  40. 40. Project Cost & Funding - 2<br />Bizplan - Confidential<br />
  41. 41. Exit Valuation<br />
  42. 42. Investment Merits<br />The contract services business for biopharmaceutical products is poised for an incremental growth in Asia due to significant cost advantages and limited competition.<br />Viropro has three Term Sheets in place to acquire key technical-, intellectual- and physical assets, and to capitalize the Alpha Biologics’ world class facility/asset in Penang, Malaysia, thereby providing the foundation for its global footprint. <br />The investments required by Viropro is for the above acquisitions and for working capital to prepare Alpha Biologics for its GMP accreditation and to going commercial.<br />Viroprohas an experienced management and technical team.<br />An investment return of ~10X and an IRR of ~46% on post-tax earnings, in the 5th year of full GMP operation, is predicated on the basis of a robust financial model.<br />
  43. 43. SECTION 4<br />Appendix<br />
  44. 44. Capitalization of Alpha Biologics into Viropro<br />Babraham Research Park<br />Babraham, Cambridgeshire <br />Penang Science Park<br />Malaysia<br />
  45. 45. Alpha Biologics Summary -1/2<br />Alpha Biologics is a bio-manufacturing organisation offering US FDA and European EMEA current Good Manufacturing Practices (cGMP) compliant services to the worldwide pharmaceutical and biotechnology industry<br />A new FDA design-reviewed 5,000m2 plant on the Penang Science Park for the manufacture of biologics drugs (including bio-similar) for pre-clinical and Phase I, II and III clinical trials<br />State-of-the-art bespoke manufacturing equipment designed, built and validated by industry experts in Europe<br />Process development laboratories located in the biotech hub of Cambridge UK, lead by highly experienced industry experts<br />
  46. 46. Alpha Biologics Summary – 2/2 <br />The facility will focus on the provision of mammalian cell culture services for the production of monoclonal antibodies and recombinant proteins<br />Future expansion could be envisaged in two stages – the first, a ‘fill/finish’ operation; the second, a microbial cell facility<br />Managed by a team of professionals with cGMP facility design and operation, and manufacturing experience in the US and Europe, Alpha will ensure the highest standards of production and regulatory compliance<br />Most, if not all, of the major contract manufacturing competitors are located in the US and Europe and costs associated with these facilities, due to their locations and size are much higher than Alpha. Thus Alpha will be able to compete aggressively on pricing while still achieving the gross and net margins required<br />

×